These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12938261)

  • 1. [Iressa (gefitinib)].
    Kudoh S; Yoshimura A; Gemma A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1079-84. PubMed ID: 12938261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
    Vansteenkiste J
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib--a novel targeted approach to treating cancer.
    Herbst RS; Fukuoka M; Baselga J
    Nat Rev Cancer; 2004 Dec; 4(12):956-65. PubMed ID: 15573117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib: phase II and III results in advanced non-small cell lung cancer.
    Kelly K; Averbuch S
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):93-9. PubMed ID: 14981586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib: a review of its use in adults with advanced non-small cell lung cancer.
    Dhillon S
    Target Oncol; 2015 Mar; 10(1):153-70. PubMed ID: 25637458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of gefitinib in lung cancer treatment.
    Giaccone G
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4233s-4237s. PubMed ID: 15217964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
    Han SW; Hwang PG; Chung DH; Kim DW; Im SA; Kim YT; Kim TY; Heo DS; Bang YJ; Kim NK
    Int J Cancer; 2005 Jan; 113(1):109-15. PubMed ID: 15386420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib, a novel, orally administered agent for the treatment of cancer.
    Ranson M; Wardell S
    J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
    Johnson DH; Arteaga CL
    J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-small-cell lung cancer third-line therapy with gefitinib].
    Fischer JR; Haffner U; Dietrich GM; Spahlinger B; Geiger D; Lahm H
    Pneumologie; 2005 May; 59(5):321-7. PubMed ID: 15902597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
    Pizzo B
    Clin J Oncol Nurs; 2004 Aug; 8(4):385-92. PubMed ID: 15354925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
    Tammaro KA; Baldwin PD; Lundberg AS
    J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
    Bogdanowicz BS; Hoch MA; Hartranft ME
    J Oncol Pharm Pract; 2017 Apr; 23(3):203-214. PubMed ID: 26911477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
    Akamatsu H; Inoue A; Mitsudomi T; Kobayashi K; Nakagawa K; Mori K; Nukiwa T; Nakanishi Y; Yamamoto N
    Jpn J Clin Oncol; 2013 Jun; 43(6):664-8. PubMed ID: 23585689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
    Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
    J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.